Breast cancer survival rates improved by novel drug sequence, say researchers

Changing the way women are treated for breast cancer could improve their overall chance of survival, according to research published today in the Lancet. The new paper shows that switching to a drug called exemestane, two to three years after commencing standard therapy with the drug tamoxifen, can cut the risk of death for certain women by a further 17% compared with using tamoxifen alone.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news90590959.html">Breast cancer survival rates improved by novel drug sequence, say researchers</a></p> <p>Changing the way women are treated for breast cancer could improve their overall chance of survival, according to research published today in the <i>Lancet</i>. The new paper shows that switching to a drug called exemestane, two to three years after commencing standard therapy with the drug tamoxifen, can cut the risk of death for certain women by a further 17% compared with using tamoxifen alone.</p>